Efficacy of tyrosine kinase inhibitors imatinib and sunitinib was approved for COL1A1-PDGFB-positive dermatofibrosarcoma treatment or involved in clinical trials of Phase I-III ([5–7] and Table 1). The gene discussed is COL1A1; the disease is dermatofibrosarcoma protuberans.